MPB-1734 new dosage form anticancer drug has passed the US FDA clinical I/IIa IND application
The MPB-1734 new dosage form anticancer drug developed by MegaPro Biomedical has passed the review of the US FDA, and the IND has been approved for clinical phase I/IIa trial. The development of new formulations of MPB-1734 is based on the nano-microcell technology platform of MegaPro Biomedical. After coating the traditional anti-cancer drugs, the drug can be concentrated on the tumor site through the nano dosage form to enhance the efficacy of the drug, and at the same time, the side effects of traditional cancer drugs are reduced. Cell and animal experiments have shown that it has a significant inhibitory effect on drug-resistant malignant tumors. Therefore, the new formulation of MPB-1734 anti-cancer drug is expected to provide better treatment options for cancer patients.
The results of pre-clinical trials of MPB-1734 new dosage form anticancer drug showed that the highest tolerated dose was three times that of the original drug, and the bone marrow function suppression reaction after injection is milder than that of the original drug. While maintaining immunity, it helps patients complete the course of treatment and improve curative effect. The results of pre-clinical trials have shown that MPB-1734, a new formulation of anticancer drug, can effectively inhibit tumor growth and increase the survival days of diseased animals. At the same time, it can present the antigens of tumor cells, so that the immune system of animals can learn and identify malignant tumors; in the animal test group with the immune node inhibitor (PD-1), combined use of low-dose MPB-1734 new dosage forms of anticancer drugs can effectively inhibit and shrink malignant tumors. In the future, it will be jointly developed with immune drugs to exert an effect of synergy.
The phase I/IIa clinical trial of MPB-1734 new dosage form anticancer drug will be carried out in a multi-country and multi-center manner. The patients who are scheduled to receive treatment are suffering from late parenchymal solid tumors. It is expected to that cases are to be accepted in 2021 and clinical trials are to be completed by the end of 2023.
About MegaPro Biomedical
Giant Biomedical is a new drug development company with nano-drugs as its core and nano-particles and nano-microcells as its technology platform. At present, the nanoparticle product MPB-1523 MRI contrast agent-liver cancer has completed the clinical phase II trial. Another MPB-1514 iron deficiency anemia iron supplement is also expected to start a clinical 2b trial in 2021, MPB-1523 is currently in contact with domestic and foreign pharmaceutical companies to discuss the feasibility of authorization; clinical phase III trials are expected to be carried out with authorized partners based on clinical phase II results. Using nano-cell technology to construct an anti-cancer drug platform, the new dosage form of MPB-1734 anti-cancer drug has also completed the IND application for clinical phase I/IIa of the US FDA. MegaPro will launch more product lines with its highly competitive nanotechnology platform, and through international collaboration, to accelerate product development for clinical use. For further company information, please visit http://www.MegaProbio.com